Ustekinumab not checked
Janssen Research & Development, LLC · CNTO1275 · CNTO 1275
FollowEvery change as it happens, and a Monday email
Trials
11 active
37 in total · 16 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Ustekinumab will be administered by IV infusion and SC injection.”In the company’s words, NCT03466411 on ClinicalTrials.gov
- Tested for
- Plaque Psoriasis, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Crohn's Disease
- Main trialPhase 3
- “The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.”In the company’s words, NCT06934226 on ClinicalTrials.gov
- Other names
- Stelara · CNTO1275 · CNTO 1275
Other drugs for Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Copies tested against it7
Other companies’ versions, mostly cheaper copies for when the patent ends
- GNR-068AO GENERIUM · NCT06488664, NCT06481215 · finished
- Bmab1200Biocon Biologics UK Ltd · NCT05335356 · finished
- FYB202Bioeq GmbH · NCT04595409 · finished
- BFI-751BioFactura Australia Pty Ltd. · NCT04843631 · finished
- CT-P43Celltrion · NCT04428814, NCT04673786 · finished
- DMB-3115Dong-A ST Co., Ltd. · NCT04785326 · finished
- SB17Samsung Bioepis Co., Ltd. · NCT04967508 · finished
Coming up1
- 29 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials37
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 17 Nov 2025 | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Active, not recruiting | 29 Sep 2027 | A Long-term Extension Study of Ustekinumab in Pediatric Participants | |
| Phase 2/3Active, not recruiting | 20 Oct 2023 | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 4Completed | 18 May 2025 | A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Completed | 10 Jun 2015 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) | |
| Phase 3Terminated | 22 Mar 2017 | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis | |
| Phase 3Terminated | 31 Aug 2017 | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis | |
| Phase 3Completed | Dec 2017 | An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age | |
| Phase 3Completed | 10 Aug 2018 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Completed | 30 Apr 2020 | Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab | |
| Phase 3Terminated | 5 Nov 2020 | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus | |
| Phase 3Completed | 15 Dec 2020 | Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year | |
| Phase 3Terminated | 24 Jan 2022 | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | |
| Phase 3Withdrawn | 31 Jan 2022 | A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus | |
| Phase 3Completed | 19 Aug 2022 | A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Terminated | 25 May 2023 | A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) | |
| Phase 3Completed | 28 Nov 2024 | A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Completed | 8 May 2025 | A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) | |
| Phase 3Completed | 12 Jan 2026 | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis | |
| Phase 2Completed | 31 May 2016 | Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) | |
| Phase 2Completed | 10 Dec 2020 | Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Withdrawn | 24 May 2023 | A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease | |
| Phase 1Completed | 19 Sep 2018 | A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | |
| Phase 1Completed | 31 Dec 2020 | Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants | |
| Phase 1Terminated | 22 Nov 2021 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | |
| Phase 1Completed | 7 Jan 2022 | A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants | |
| Phase 1Completed | 26 Jan 2024 | A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis | |
| Phase 4Authorised | not given | Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis | |
| Phase 2Authorised | not given | Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial. | |
| Phase 2Authorised | not given | Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING). | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 2Ended | not given | PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease | |
| Phase 3/4Ended | not given | An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation study (REScUE-OLE) | |
| Phase 2Authorised | not given | BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch | |
| Phase 3Authorised | not given | FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial | |
| Phase 4Authorised | not given | MOVE-IT: MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independant Randomized Controlled Trial | |
| Phase 2Authorised | not given | Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026